NEOADJUVANT WEEKLY NAB-PACLITAXEL PLUS CARBOPLATIN FOLLOWED BY DOXORUBICIN PLUS CYCLOPHOSPHAMIDE WITH BEVACIZUMAB ADDED CONCURRENTLY TO CHEMOTHERAPY FOR OPERABLE TRIPLE-NEGATIVE INVASIVE BREAST CANCER

NEOADJUVANT WEEKLY NAB-PACLITAXEL PLUS CARBOPLATIN FOLLOWED BY DOXORUBICIN PLUS CYCLOPHOSPHAMIDE WITH BEVACIZUMAB ADDED CONCURRENTLY TO CHEMOTHERAPY FOR OPERABLE TRIPLE-NEGATIVE INVASIVE BREAST CANCER

Purpose: This phase II neoadjuvant study investigated whether nab paclitaxel, carboplatin and bevacizumab given before neoadjuvant doxorubicin/cyclophosphamide (AC) produced higher pathologic complete response (pCR) rates in triple- negative breast cancer (TNBC) compared with historical results ach...

Full description

Bibliographic Details
Main Authors: Jasgit C. Sachdev, Jessica N. Snider, Jeffrey W. Allen, Lee S. Schwartzberg, Robyn R. Young, Ahmed Y. Javed, Matthew P. Smeltzer, Furhan Yunus, Carmel S. Verrier, Mohammad Jahanzeb
Format: Article
Language:English
Published: Shaukat Khanum Memorial Trust 2016-05-01
Series:Journal of Cancer and Allied Specialties
Online Access:http://journals.sfu.ca/jcas/index.php/jcas/article/view/59

Internet

http://journals.sfu.ca/jcas/index.php/jcas/article/view/59

Similar Items